Halozyme Fair Value
RV
The fair market value of RV7.SW stock is 54.07 CHF. Relative to the market price of 0 CHF Halozyme is undervalued by 24.2%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Halozyme Valuation
The fair value level of 54.07 CHF can be considered as an effective entry point for long-term investors to start investing in RV7.SW stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Market price:
RV7.SW stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Halozyme Therapeutics Inc Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
38.07
2
Median P/E over 5 years
19.85
3
Minimum P/E over 5 years
14.15
4
Earning per share (last 12 months)
3.07 USD
Maximum value
1
x
4
=
103.7 CHF
Fair value
2
x
4
=
54.07 CHF
Minimum value
3
x
4
=
38.55 CHF
Halozyme Therapeutics Inc price metrics
19.33
Annual return (geometric mean)
41.42
Risk (standard deviation) of returns
β
1.31
Beta (volatility compared to market)